|royalty pharma ag||1.85||0.7||9316||20|
|royalty pharma group holdings sa||0.83||0.5||7140||48|
|royalty pharma general counsel||0.3||0.2||8744||23|
|royalty pharma aktie||0.1||0.6||8061||18|
|royalty pharma aktienkurs||0.79||0.8||7048||86|
|royalty pharma azioni||0.35||0.3||704||24|
|royalty pharma address||0.2||0.1||2225||78|
|royalty pharma analyst||1.81||0.6||9883||66|
|royalty pharma analyst coverage||1.09||0.2||6265||52|
|royalty pharma ag stock||1.43||0.5||6560||56|
|royalty pharma epizyme agreement||0.24||0.8||6042||66|
|agios royalty pharma||1.1||0.4||1263||70|
About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceuticWhen will Royalty Pharma plc pay a dividend?
NEW YORK, NY, July 16, 2021 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of $0.17 per class A ordinary share. The dividend will be paid on September 15, 2021, to shareholders of record at the close of business onHow much did Royalty Pharma offer in 2021?
NEW YORK, NY, July 15, 2021 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.3 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $600 million of 2.15% Senior Notes due 2031 (the “Social Bonds”)